Ypsomed Holding AG
SIX:YPSN
Intrinsic Value
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. [ Read More ]
The intrinsic value of one
YPSN
stock under the Base Case scenario is
269.94
CHF.
Compared to the current market price of 365 CHF,
Ypsomed Holding AG
is
Overvalued by 26%.
Ypsomed Holding AG's market capitalization is 5B CHF.
YPSN stock price is 365 CHF.
YPSN stock (269.94 CHF) is 26% less than its price (365 CHF).
YPSN stock (360.24 CHF) is 1% less than its price (365 CHF). Open Relative Valuation
YPSN has downside potential of 8% compared to the average analyst price target.
Open Wall St Estimates
YPSN's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
YPSN's Revenue has grown by 5% over the past 12 months.
YPSN's ROE (Return on Equity) for the past 12 months is positive and is equal to 13%.
YPSN has positive Operating Income for the last twelve months.
YPSN has positive Net Income for the last twelve months.
YPSN's Revenue has been growing by 8% per year for the last 3 years.
YPSN's ROIC (Return on Invested Capital) has increased in the last 3 years from 0% to 9%.
YPSN has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
YPSN's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
YPSN's ROE (Return on Equity) has significantly increased in the last 3 years from 2% to 13%.
YPSN has positive Gross Profit for the last twelve months.
YPSN has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
YPSN's short-term liabilties (322m CHF) exceed its short-term assets (249m CHF).
YPSN's long-term assets (937m CHF) exceed its long-term liabilties (363m CHF).
YPSN's D/E (Debt to Equity) is very low and is equal to 0.35.
YPSN has positive Net Debt. This means that the company has more debt (203m CHF) than cash and short-term investments (36m CHF).
YPSN has negative Free Cash Flow for the last twelve months.
YPSN's Altman Z-Score is very high and is equal to 8.12.
Valuation Backtest
Ypsomed Holding AG
Run backtest to discover the historical profit from buying and selling
YPSN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ypsomed Holding AG
Balance Sheet Decomposition
Ypsomed Holding AG
| Current Assets | 249.3m |
| Cash & Short-Term Investments | 36.4m |
| Receivables | 95.8m |
| Other Current Assets | 117.1m |
| Non-Current Assets | 687.4m |
| Long-Term Investments | 2.6m |
| PP&E | 397.8m |
| Intangibles | 256.9m |
| Other Non-Current Assets | 30.1m |
| Current Liabilities | 322.3m |
| Accounts Payable | 24.6m |
| Accrued Liabilities | 45.6m |
| Short-Term Debt | 203m |
| Other Current Liabilities | 49m |
| Non-Current Liabilities | 40.7m |
| Other Non-Current Liabilities | 40.7m |
Earnings Waterfall
Ypsomed Holding AG
|
Revenue
|
508.6m
CHF
|
|
Cost of Revenue
|
-345.6m
CHF
|
|
Gross Profit
|
163m
CHF
|
|
Operating Expenses
|
-81.9m
CHF
|
|
Operating Income
|
81m
CHF
|
|
Other Expenses
|
-8.6m
CHF
|
|
Net Income
|
72.4m
CHF
|
Free Cash Flow Analysis
Ypsomed Holding AG
What is Free Cash Flow?
YPSN Profitability Score
Profitability Due Diligence
Ypsomed Holding AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Ypsomed Holding AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
YPSN Solvency Score
Solvency Due Diligence
Ypsomed Holding AG's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Ypsomed Holding AG's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YPSN Price Targets Summary
Ypsomed Holding AG
According to Wall Street analysts, the average 1-year price target for
YPSN
is 336.6 CHF
with a low forecast of 333.3 CHF and a high forecast of 346.5 CHF.
Shareholder Return
YPSN Price
Ypsomed Holding AG
| Average Annual Return | 7.89% |
| Standard Deviation of Annual Returns | 15.4% |
| Max Drawdown | -33% |
| Market Capitalization | 5B CHF |
| Shares Outstanding | 13 629 979 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Ypsomed Holding AG
Country
Industry
Market Cap
Dividend Yield
Description
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. The company is headquartered in Burgdorf, Bern and currently employs 1,900 full-time employees. The company went IPO on 2004-09-22. The firm develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The firm operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The firm operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Contact
IPO
Employees
Officers
The intrinsic value of one
YPSN
stock under the Base Case scenario is
269.94
CHF.
Compared to the current market price of 365 CHF,
Ypsomed Holding AG
is
Overvalued by 26%.
You don't have any saved screeners yet
